US · Healthcare · Biotechnology
EPS came in at -0.42 against a street estimate of -0.60 — a beat of 30.0%.
Analysts rate BridgeBio Pharma Inc a strong buy (21 buy, 2 hold, 0 sell out of 23) with an average price target of $107.81.
CONFIDENT Attruby delivered $253.2 million of U.S. revenue, while three priority-review launches approach: BBP-418 in November, infigratinib in February, and encaleret in May. Q3 FY26 Management described Attruby-Beyonttra as annualizing above $1 billion globally, with Attruby leading in Europe and royalty revenue primarily from Europe and Japan. Analysts focused on Attruby’s growth trajectory, launch financing, payer access, regulatory risks and the broader encaleret opportunity. Management responded with confidence in commercial execution, launch readiness and disciplined capital allocation. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| Jupiter Topco LLC | 7.22% |
| Kohlberg Kravis Roberts & Co LP | 6.78% |
| HHG PLC | 6.74% |
| Farallon Capital Management, L.L.C. | 5.50% |
| BlackRock Inc | 5.26% |
| Viking Global Investors LP | 5.09% |
| Vanguard Capital Management, LLC | 4.04% |
| Vanguard Portfolio Management, LLC | 3.92% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $353,171 thousand, up from $120,700 thousand in the third quarter of 2025. • Nine-month 2026 reven | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $353.2 million, up from $120.7 million in the same quarter of 2025. • U.S. Attruby net product rev | 2026-10-29 |
| Company announcement · Q4 2026 HEADLINE NUMBERS • On October 6, 2026, BridgeBio Pharma announced that the U.S. FDA accepted its New Drug Application (NDA) for oral infigratinib in | 2026-10-13 |
| Company announcement · Q3 2026 BRIDGEBIO PHARMA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Document date: August 31, 2026 • Company: BridgeBio Pharma, Inc. (NASDAQ: BBIO) • Headq | 2026-08-31 |
| Material agreement · Q3 2026 BRIDGEBIO PHARMA, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Secondary offering of 5,000,000 shares of common stock by selling stockholder KKR Genet | 2026-08-17 |
| Quarterly report · Q2 2026 BRIDGEBIO PHARMA, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net product revenue Q2 2026: $222.4 million (vs. $71.5 million in Q2 2025) — 211% i | 2026-08-10 |
| Results announced · Q3 2026 BRIDGEBIO PHARMA Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 total revenues: $243.7 million (vs. $110.6 million in Q2 2025) • Attru | 2026-08-10 |
| Company announcement · Q3 2026 BRIDGEBIO PHARMA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: BridgeBio Pharma, Inc. (Ticker: BBIO, Listed on Nasdaq Global Select Market) • | 2026-07-22 |
Readable in the app.
| Announcement | Date |
|---|---|
| Company raises $933.9M in preferred stock investment from multiple investors BridgeBio Pharma raised $933.9 million on July 1, 2026, by issuing preferred stock to two investors: Sixth Street Partners ($800M for 800,000 shares) and KKR affiliate HCRx ($133.9M for 133, | 2026-07-02 |
| NDA submitted to FDA for encaleret for ADH1 treatment BridgeBio Pharma submitted a New Drug Application (NDA) to the FDA for encaleret, a potential first-in-class treatment for autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic calci | 2026-05-13 |
| Board approves $500 million stock repurchase program BridgeBio Pharma reported Q1 2026 financial results on May 7, 2026. The 8-K filing does not disclose specific financial metrics, revenue figures, or operational details—these were included i | 2026-05-07 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BridgeBio Pharma Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.